Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) has scheduled a conference call for November 8, 2022, at 5:00 PM ET to review its Q3 2022 financial results, recent business developments, and 2022 financial outlook. Investors can join via webcast or by phone after registering. A replay will be accessible on the company’s investor page. Emergent BioSolutions focuses on defending public health threats through vaccines and therapeutics and aims to enhance the lives of one billion people by 2030.

Positive

• Scheduled conference call to discuss Q3 2022 financial results and outlook

Negative

• None.

GAITHERSBURG, Md., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, November 8, 2022, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2022, recent business developments, and financial outlook for full year 2022.

Conference Call Information
Participants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 20 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, Twitter, and Instagram.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com  

Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com

FAQ

What date is Emergent BioSolutions planning to announce its Q3 2022 earnings?

Emergent BioSolutions will announce its Q3 2022 earnings on November 8, 2022.

How can I participate in the Emergent BioSolutions earnings call?

Participants can join the Emergent BioSolutions earnings call via webcast or by telephone after registering through the provided link.

What information will be discussed during the Emergent BioSolutions conference call?

The conference call will cover Q3 2022 financial results, recent business developments, and the financial outlook for full year 2022.

Where can I find the replay of the Emergent BioSolutions earnings call?

A replay of the earnings call will be available on the Emergent BioSolutions investor page.